中文摘要：

近年来，抗丙型肝炎病毒（HCV）感染的治疗取得了很好的进展，特别是直接作用抗病毒药物（direct-acting antivirala．gents，DAAs）的快速发展，使HCV感染的治愈提上日程，但DAAs的长期应用不可避免地会产生病毒耐药。导致治疗失败。为解决这一问题，宿主靶向药物（host—targeting agents，HTAs）的研发是重要策略之一。HTAs通过靶向作用于HCV生命周期各个阶段所必需的宿主因子，能有效减少病毒耐药并具有泛基因型抗病毒优势，与DAAs联合应用还具有协同抗病毒的效果并可降低药物毒副作用。笔者综述了现阶段临床前和临床在研的HTAs，为研发新型的抗HCV药物提供参考。

英文摘要：

Recently, the therapy of hepatitis C virus （HCV） infection, especially with the direct-acting antiviral agents （ DAAs）, has achieved many progresses. Although it is expected to cure HCV infection completely in the coming future, long-term application of DAAs will inevitably induce virus resistance, resulting in treatment failure. To solve this key problem, development of host-targeting a- gents （HTAs） emerges as one of effective strategies. HTAs targets the essential host factors for various stages of HCV life cycle, and thus has several advantages against HCV with reducing viral resistance, pan-genotypic antivirus, synergistic antiviral effects combined with known DAAs and decreasing side effects of drugs. This review summarized the recent progress of investigating HTAs in the pre- clinical and clinical study, to provide clues for the development of new anti-HCV drugs.